Get 40% Off
🚨 Volatile Markets? Find Hidden Gems for Serious Outperformance
Find Stocks Now

Si-Bone director sells shares worth over $40,000

Published 14/03/2024, 21:48
© Reuters.

SI-Bone, Inc. (NASDAQ:SIBN) director Mika Nishimura has recently sold a portion of her holdings in the company. According to the latest filings, Nishimura disposed of 2,500 shares of common stock at a price of $16.22 per share. The total value of the sale amounted to approximately $40,550.

This transaction has adjusted Nishimura's stake in the company, leaving her with 19,350 shares of SI-Bone, Inc. remaining in her possession. It should be noted that this figure includes 5,550 shares issuable upon the settlement of restricted stock units granted to Nishimura, which represent a contingent right to receive shares of the company's common stock.

SI-Bone, Inc., based in Santa Clara, California, specializes in surgical and medical instruments and apparatus. The company is known for its innovative medical devices used in the surgical treatment of musculoskeletal disorders.

Investors often monitor insider transactions such as these for insights into the confidence levels of a company's executives and directors. However, such transactions can occur for a variety of reasons and may not necessarily reflect the insider's view of the company's future prospects.

The sale by Nishimura was executed on March 13, 2024, and was formally documented the following day. The transaction was made public through a Form 4 filing with the Securities and Exchange Commission.

InvestingPro Insights

In light of the recent insider transaction at SI-Bone, Inc. (NASDAQ:SIBN), where director Mika Nishimura sold a portion of her shares, a closer look at the company's financial health and stock performance through InvestingPro metrics and tips can provide investors with additional context.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

InvestingPro data shows that SI-Bone, Inc. holds a market capitalization of $663.19 million, which gives a sense of the company's size in the competitive medical device market. The company's P/E ratio stands at -14.30, reflecting market sentiment about its earnings potential. The negative P/E ratio indicates that SI-Bone is currently not profitable, a detail that aligns with one of the InvestingPro Tips which suggests that analysts do not anticipate the company will be profitable this year.

The stock's performance has been under scrutiny, with the price having taken a significant hit over the last week, showing a -9.52% return. This short-term decline is part of a broader negative trend, with the stock experiencing a -20.83% return over the last month. This performance is crucial for investors to consider, especially in the context of insider sales.

However, not all indicators are negative. An InvestingPro Tip highlights that SI-Bone holds more cash than debt on its balance sheet, which could suggest a degree of financial stability. Additionally, the company's liquid assets exceed its short-term obligations, which may provide some reassurance to investors concerned about the company's ability to meet its immediate financial commitments.

For those interested in a deeper dive into SI-Bone's financials and stock performance, there are additional InvestingPro Tips available. These insights can help investors make more informed decisions, and with the use of the coupon code PRONEWS24, they can get an extra 10% off a yearly or biyearly Pro and Pro+ subscription. Visit https://www.investing.com/pro/SIBN to explore further and unlock the full suite of tips and metrics.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.